KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Amortization of Deferred Charges (2016 - 2020)

Novavax (NVAX) has 5 years of Amortization of Deferred Charges data on record, last reported at $356000.0 in Q4 2020.

  • For Q4 2020, Amortization of Deferred Charges changed 0.0% year-over-year to $356000.0; the TTM value through Dec 2020 reached $1.4 million, changed 0.0%, while the annual FY2020 figure was $1.4 million, 0.0% changed from the prior year.
  • Amortization of Deferred Charges reached $356000.0 in Q4 2020 per NVAX's latest filing, roughly flat from $356000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $356000.0 in Q2 2016 and bottomed at $237000.0 in Q1 2016.
  • Average Amortization of Deferred Charges over 5 years is $350050.0, with a median of $356000.0 recorded in 2016.
  • The widest YoY moves for Amortization of Deferred Charges: up 50.21% in 2017, down 0.0% in 2017.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $356000.0 in 2016, then changed by 0.0% to $356000.0 in 2017, then changed by 0.0% to $356000.0 in 2018, then changed by 0.0% to $356000.0 in 2019, then changed by 0.0% to $356000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $356000.0 in Q4 2020, $356000.0 in Q3 2020, and $356000.0 in Q2 2020.